KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Travere Therapeutics (TVTX) over the last 17 years, with Q3 2025 value amounting to $18.2 million.

  • Travere Therapeutics' Accounts Payables fell 2142.7% to $18.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.2 million, marking a year-over-year decrease of 2142.7%. This contributed to the annual value of $23.5 million for FY2024, which is 4352.97% down from last year.
  • Per Travere Therapeutics' latest filing, its Accounts Payables stood at $18.2 million for Q3 2025, which was down 2142.7% from $19.1 million recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' Accounts Payables ranged from a high of $41.7 million in Q4 2023 and a low of $5.8 million during Q3 2021
  • Moreover, its 5-year median value for Accounts Payables was $17.3 million (2022), whereas its average is $18.5 million.
  • In the last 5 years, Travere Therapeutics' Accounts Payables skyrocketed by 14103.53% in 2023 and then crashed by 4352.97% in 2024.
  • Over the past 5 years, Travere Therapeutics' Accounts Payables (Quarter) stood at $15.1 million in 2021, then rose by 14.17% to $17.3 million in 2022, then skyrocketed by 141.04% to $41.7 million in 2023, then plummeted by 43.53% to $23.5 million in 2024, then fell by 22.56% to $18.2 million in 2025.
  • Its Accounts Payables stands at $18.2 million for Q3 2025, versus $19.1 million for Q2 2025 and $15.4 million for Q1 2025.